Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB4 autoinjector versus pre-filled syringe pharmacokinetic crossover study in healthy men
NL-OMON45442Active, not recruiting
- Sponsor
- Samsung Bioepis
- Start
- Apr 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of etanercept in autoimmune disease, rheumatoid arthritis (RA) and psoriasis (2 arms), sponsored by Samsung Bioepis. Primary endpoints: Bioequivalence based on AUCinf, Bioequivalence based on AUClast and 1 more. Started Apr 2017; status: active, not recruiting.
02
Drugs
etanercept
03
Conditions
autoimmune diseaserheumatoid arthritis (RA)psoriasis
Beyond the preview
Go deeper on NL-OMON45442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45442.